Condition: Lichen Sclerosus · Sponsor: LEO Pharma
The main objective of the study is to evaluate the efficacy of twice daily applications of delgocitinib cream compared with cream vehicle in the treatment of adult participants with mild to severe lichen sclerosus (LS). The researchers are focusing on female participants because LS is more likely to affect females compared to males. The trial is conducted in 2 parts. Part 1 of the trial enrolls female participants with LS and results in the selection of the optimal dose for Part 2. The selected dose will then be evaluated in Part 2, which will enroll both female and male participants. Assessment of efficacy and safety of delgocitinib cream in male participants with LS will be evaluated in a substudy. For each participant, the trial will last at least 55 weeks and up to 60 weeks.
This description comes directly from the study's public registry record.
Clinical Disclosure · (+45) 4494 5888 · disclosure@leo-pharma.com
Always discuss trial participation with your own doctor first.
| LEO Pharma Investigational Site | Birmingham, Alabama, United States | Recruiting |
| LEO Pharma Investigational Site | Washington D.C., District of Columbia, United States | Recruiting |
| LEO Pharma Investigational Site | Miami, Florida, United States | Recruiting |
| LEO Pharma Investigational Site | Tamarac, Florida, United States | Recruiting |
| LEO Pharma Investigational Site | New York, New York, United States | Recruiting |
| LEO Pharma Investigational Site | Montreal, Quebec, Canada | Recruiting |
| LEO Pharma Investigational Site | Québec, Quebec, Canada | Recruiting |
Get one email when the public record changes — results posted, or the study's status changes. Nothing else, ever.
We email about this public record only. Unsubscribe anytime with one click. Never medical advice.
This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.
Source record: clinicaltrials.gov/study/NCT07335588